Keyword: Turing Pharmaceuticals
As high as U.S. drug costs may be, they’re dwarfed by hospital and physician expenses. Can pharma make its drugs-save-money argument stick?
After an upswing in pharma's global reputation in 2015, its standing among patient groups has swung the other way—again.
Ex-Turing Pharma CEO Martin Shkreli can’t get away from his bad rep.
Pharma has heard enough of New York Governor Andrew Cuomo’s ideas to lower drug prices, and it's lobbying state officials to oppose it, too.
A new report commissioned by industry group PhRMA lends credibility to the argument that a complex distribution system plays a role in high drug costs.
We won’t surprise anyone by saying that Topic No. 1 in pharma this year was drug pricing. We’ll give you one guess as to whether 2017 will be more of the same.
After a yearlong investigation into rising drug prices, the U.S. Senate has released a report that seeks to provide solutions to a tough conundrum: Legislators don’t want the government to intervene in pharmaceutical pricing, but they do want to prevent pharma companies from buying old drugs and then reaping huge profits from them by charging outrageous prices.
Share prices for leading generics companies took a big hit Thursday on news that the Department of Justice could file collusion charges by year’s end, a probe first unveiled by Bloomberg.
High-powered industry group PhRMA is raising hundreds of millions to fund a counteroffensive against drug-pricing action in the wake of next month's election.
Industry watchers wondering which biopharma company will land in hot water next for big price hikes may have their answer. Sen. Bernie Sanders and Rep. Elijah Cummings, who often have a hand in pharma affairs, have homed in on “staggering” price increases by Ariad Pharmaceuticals for leukemia drug Iclusig.